HC Wainwright Increases Savara (NASDAQ:SVRA) Price Target to $10.00

Savara (NASDAQ:SVRA) had its target price hoisted by research analysts at HC Wainwright from $6.00 to $10.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 160.42% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. Oppenheimer upped their target price on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of Savara in a research note on Monday, May 6th. Piper Sandler boosted their price target on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Finally, Evercore ISI reduced their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, May 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $10.50.

Savara Price Performance

Shares of NASDAQ SVRA opened at $3.84 on Thursday. The firm’s 50-day simple moving average is $4.36 and its 200 day simple moving average is $4.64. The stock has a market cap of $530.65 million, a P/E ratio of -10.38 and a beta of 0.70. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22. Savara has a fifty-two week low of $2.60 and a fifty-two week high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities analysts expect that Savara will post -0.41 EPS for the current year.

Hedge Funds Weigh In On Savara

A number of institutional investors have recently bought and sold shares of the stock. Bain Capital Life Sciences Investors LLC boosted its holdings in shares of Savara by 2.3% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock worth $72,536,000 after buying an additional 332,706 shares during the period. Jennison Associates LLC boosted its position in shares of Savara by 0.3% in the first quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after buying an additional 26,613 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in Savara by 30.9% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock valued at $30,008,000 after acquiring an additional 1,874,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Savara by 2.5% in the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after acquiring an additional 148,673 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after acquiring an additional 746,407 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.